Boehringer Ingelheim licensed Yuhan's first-in-class GLP-1/FGF21 dual agonist (a long-acting fusion protein using Genexine HyFc technology) for NASH and related liver disease. Yuhan received $40M upfront and near-term payments and is eligible for up to $830M in milestones plus tiered royalties.